Drugs / OCPM Immunotherapeutic Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00674791 | Jun 2007 → Jan 2010 | breast cancer | Duke University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OCPM Immunotherapeutic Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00674791 ↗ |
| Modality | Vaccine | “a peptide vaccine consisting of twelve different tumor-rejection antigens” NCT00674791 ↗ |
| Route | Subcutaneous | “They will receive the peptide vaccine subcutaneously” NCT00674791 ↗ |